Prostate cancer is the most commonly diagnosed cancer affecting men in the United States.
The prostate is a hormone-dependent gland in which androgen hormones testosterone and …

Metastatic Prostate Cancer Interventions added to androgen-deprivation therapy in men with
metastatic prostate cancer have recently been noted to increase survival. Decisions about …

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis,
risk stratification and workup, treatment options for localized disease, and management of …

Background Patients with metastatic castration-resistant prostate cancer and homologous
recombination repair (HRR) mutations have a better response to treatment with the poly …

During the past 10 years, preclinical studies implicating sustained androgen receptor (AR)
signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to …

Background Androgen deprivation therapy (ADT) is foundational in the management of
advanced prostate cancer (PCa) and has benefitted from a recent explosion in scientific …

Prostate cancer is a hormone-dependent malignancy, whose onset and progression are
closely related to the activity of the androgen receptor (AR) signaling pathway. Due to this …

Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …

Background Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall
survival in patients with metastatic castration-resistant prostate cancer after chemotherapy …

The treatment of advanced prostate cancer has been transformed by novel antiandrogen
therapies such as enzalutamide. Here, we identify induction of glucocorticoid receptor (GR) …